Logo image of APUS

APIMEDS PHARMACEUTICALS US I (APUS) Stock Fundamental Analysis

USA - NYSEARCA:APUS - US03771D1028 - Common Stock

1.8103 USD
+0.01 (+0.57%)
Last: 10/15/2025, 1:39:53 PM
Fundamental Rating

3

Taking everything into account, APUS scores 3 out of 10 in our fundamental rating. APUS was compared to 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for APUS as it has an excellent financial health rating, but there are worries on the profitability. APUS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

APUS had negative earnings in the past year.
APUS Yearly Net Income VS EBIT VS OCF VS FCFAPUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -200K -400K -600K -800K -1M

1.2 Ratios

APUS has a Return On Assets of -13.18%. This is amongst the best in the industry. APUS outperforms 82.84% of its industry peers.
Looking at the Return On Equity, with a value of -14.27%, APUS belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
Industry RankSector Rank
ROA -13.18%
ROE -14.27%
ROIC N/A
ROA(3y)-7193.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APUS Yearly ROA, ROE, ROICAPUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

APUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APUS Yearly Profit, Operating, Gross MarginsAPUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, APUS has about the same amount of shares outstanding.
The debt/assets ratio for APUS is higher compared to a year ago.
APUS Yearly Shares OutstandingAPUS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M 10M
APUS Yearly Total Debt VS Total AssetsAPUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200K 400K 600K

2.2 Solvency

APUS has an Altman-Z score of 16.49. This indicates that APUS is financially healthy and has little risk of bankruptcy at the moment.
APUS's Altman-Z score of 16.49 is amongst the best of the industry. APUS outperforms 89.74% of its industry peers.
There is no outstanding debt for APUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.49
ROIC/WACCN/A
WACCN/A
APUS Yearly LT Debt VS Equity VS FCFAPUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 -500K -1M

2.3 Liquidity

A Current Ratio of 12.79 indicates that APUS has no problem at all paying its short term obligations.
APUS has a better Current ratio (12.79) than 86.38% of its industry peers.
APUS has a Quick Ratio of 12.79. This indicates that APUS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 12.79, APUS belongs to the best of the industry, outperforming 86.38% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.79
Quick Ratio 12.79
APUS Yearly Current Assets VS Current LiabilitesAPUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 200K 400K 600K 800K 1M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for APUS have decreased strongly by -78.72% in the last year.
EPS 1Y (TTM)-78.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APUS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APUS Price Earnings VS Forward Price EarningsAPUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APUS Per share dataAPUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APIMEDS PHARMACEUTICALS US I

NYSEARCA:APUS (10/15/2025, 1:39:53 PM)

1.8103

+0.01 (+0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.3%
Inst Owner Change0%
Ins Owners13.29%
Ins Owner Change43.24%
Market Cap22.77M
AnalystsN/A
Price TargetN/A
Short Float %3.28%
Short Ratio0.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.34
P/tB 2.34
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.77
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.18%
ROE -14.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-7193.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.79
Quick Ratio 12.79
Altman-Z 16.49
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-78.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-70.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.84%
OCF growth 3YN/A
OCF growth 5YN/A